

Identification of ten loci associated with height highlights new biological pathways in human growth

Guillaume Lettre^{1,2}, Anne U Jackson^{3,25}, Christian Gieger^{4,5,25}, Fredrick R Schumacher^{6,7,25}, Sonja I Berndt^{8,25}, Serena Sanna^{3,9,25}, Susana Eyheramendy^{4,5}, Benjamin F Voight^{1,10}, Johannah L Butler², Candace Guiducci¹, Thomas Illig⁴, Rachel Hackett¹, Iris M Heid^{4,5}, Kevin B Jacobs¹¹, Valeriya Lyssenko¹², Manuela Uda⁹, The Diabetes Genetics Initiative²⁴, FUSION²⁴, KORA²⁴, The Prostate, Lung Colorectal and Ovarian Cancer Screening Trial²⁴, The Nurses' Health Study²⁴, SardiNIA²⁴, Michael Boehnke³, Stephen J Chanock¹³, Leif C Groop^{12,14}, Frank B Hu^{6,7,15}, Bo Isomaa^{16,17}, Peter Kraft⁷, Leena Peltonen^{1,18,19}, Veikko Salomaa²⁰, David Schlessinger²¹, David J Hunter^{1,6,7,15}, Richard B Hayes⁸, Gonçalo R Abecasis³, H-Erich Wichmann^{4,5}, Karen L Mohlke²² & Joel N Hirschhorn^{1,2,23}

Height is a classic polygenic trait, reflecting the combined influence of multiple as-yet-undiscovered genetic factors. We carried out a meta-analysis of genome-wide association study data of height from 15,821 individuals at 2.2 million SNPs, and followed up the strongest findings in >10,000 subjects. Ten newly identified and two previously reported loci were strongly associated with variation in height (P values from 4×10^{-7} to 8×10^{-22}). Together, these 12 loci account for ~2% of the population variation in height. Individuals with ≤ 8 height-increasing alleles and ≥ 16 height-increasing alleles differ in height by ~3.5 cm. The newly identified loci, along with several additional loci with strongly suggestive associations, encompass both strong biological candidates and unexpected genes, and highlight several pathways (*let-7* targets, chromatin remodeling proteins and Hedgehog signaling) as important regulators of human stature. These results expand the picture of the biological regulation of human height and of the genetic architecture of this classical complex trait.

The advent of genome-wide association studies¹, made possible by knowledge gained from the HapMap Consortium² and recent advances in genome-wide genotyping technologies and analytic methods, have had a dramatic impact on the field of human genetics. Recent genome-wide studies have led to the identification of common genetic variants reproducibly associated with complex human diseases³. Genome-wide association (GWA) studies have also been used

successfully to identify genetic variation associated with quantitative traits, such as lipid levels⁴ and body mass index^{5,6}. These discoveries, through the identification of previously unknown and often unanticipated genes, have opened an exciting period in the study of human complex traits and common diseases.

The small effect sizes that have characterized most of the variants recently identified present a challenge to the study of polygenic

¹Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA. ²Divisions of Genetics and Endocrinology and Program in Genomics, Children's Hospital, Boston, Massachusetts 02115, USA. ³Center for Statistical Genetics, Department of Biostatistics, University of Michigan, Ann Arbor, Michigan 48109, USA. ⁴Institute of Epidemiology, GSF National Research Center for Environment and Health, 85764 Neuherberg, Germany. ⁵Department of Epidemiology, Institute of Medical Informatics, Biometry and Epidemiology, University of Munich, 81377 Munich, Germany. ⁶Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA. ⁷Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA. ⁸Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute (NCI), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), Bethesda, Maryland 20892, USA. ⁹Istituto di Neurogenetica e Neurofarmacologia (INN), Consiglio Nazionale delle Ricerche, c/o Cittadella Universitaria di Monserrato, Monserrato, Cagliari 09042, Italy. ¹⁰Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. ¹¹Bioinformed Consulting Services, Gaithersburg, Maryland 20877, USA. ¹²Department of Clinical Sciences, Diabetes and Endocrinology, University Hospital Malmö, Lund University, 205 02 Malmö, Sweden. ¹³Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, NCI, NIH, DHHS, Bethesda, Maryland 20892, USA. ¹⁴Department of Medicine, Helsinki University Central Hospital, and Research Program for Molecular Medicine, University of Helsinki, Helsinki, Finland. ¹⁵Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA. ¹⁶Malmiska Municipal Health Center and Hospital, Jakobstad, Finland. ¹⁷Folkhälsan Research Center, Helsinki, Finland. ¹⁸Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK. ¹⁹Department of Molecular Medicine, National Public Health Institute and Department of Medical Genetics, University of Helsinki, FI-00014 Helsinki, Finland. ²⁰Department of Epidemiology and Health Promotion, National Public Health Institute, FI-00300 Helsinki, Finland. ²¹Gerontology Research Center, National Institute on Aging, 5600 Nathan Shock Drive, Baltimore, Maryland 21224, USA. ²²Department of Genetics, University of North Carolina, Chapel Hill, North Carolina 27599, USA. ²³Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA. ²⁴A full list of authors and affiliations appears in the **Supplementary Note** online. ²⁵These authors contributed equally to this work. Correspondence should be addressed to J.N.H. (joelh@broad.mit.edu).




Figure 1 Quantile-quantile plot of ~ 2.2 million SNPs for each of the six genome-wide association scans meta-analyzed. (a) DGI ($n = 2,978$). (b) FUSION ($n = 2,371$). (c) KORA ($n = 1,644$). (d) NHS ($n = 2,286$). (e) PLCO ($n = 2,244$). (f) SardiNIA ($n = 4,305$). Each black circle represents an observed statistic (defined as the $-\log_{10}(P)$) versus the corresponding expected statistic. The gray line corresponds to the null distribution.

diseases and traits, as large sample sizes have generally been required to identify associated common variants. It is not yet known whether increasing sample size further will accelerate the pace of discovery, and to what extent multiple loci with modest effect will reveal previously unsuspected biological pathways. To begin to answer these important questions, we used adult height as a model phenotype. Adult height is a complex trait with high heritability ($h^2 \sim 0.8\text{--}0.9$ within individual populations)^{7,8}. Furthermore, height is accurately measured and relatively stable over a large part of the lifespan⁹, and data is available for very large numbers of individuals. Thus, the study of height is an ideal opportunity to dissect the architecture of a highly polygenic trait in humans. In addition, because height is associated with several common human diseases (for example, cancers)¹⁰, loci associated with height may be pleiotropic, influencing the risk or severity of other diseases¹¹.

Using data from GWA studies, we and our colleagues identified the first two common variants to be robustly associated with adult height variation: a SNP in the 3' UTR of the *HMGA2* gene¹² and a SNP at the *GDF5-UQCC* locus¹¹. The overall variation in height explained by these two polymorphisms is small (0.3–0.7% of the total variance), suggesting that most common variants that influence height will have a small effect. The modest effects observed also highlight the importance of using large datasets to identify 'true' stature variants: the *HMGA2* SNP was first found in a combined analysis of the DGI and Wellcome Trust Case Control Consortium UKT2D datasets ($n = 4,921$ individuals), and the *GDF5-UQCC* finding was identified initially in an analysis of the SardiNIA and FUSION results ($n = 6,669$ individuals). As these findings are likely to be among the upper range of effect sizes for common variants associated with height, we considered the likely possibility that progressively larger sample sizes would be required to identify additional height loci.


Encouraged by these earlier successes, we proceeded to carry out a larger meta-analysis of six GWA datasets, including height association results for 15,821 individuals at ~ 2.2 million SNPs, to find additional loci associated with height. Here we report the identification and

validation of ten newly identified associations between common SNPs and height variation (each with $P < 5 \times 10^{-7}$), and an additional four associations with strongly suggestive evidence (each with $P < 5 \times 10^{-6}$). We also confirm the two previously reported associations (*HMGA2* and *GDF5-UQCC*). The newly identified loci associated with height implicate several biological pathways or gene sets—including targets of the *let-7* microRNA, chromatin remodeling proteins and Hedgehog signaling—as important regulators of human stature. Finally, we examine the interaction with gender, test for epistatic interactions between loci, and estimate the explanatory power of each locus individually and in combination. These results broaden our understanding of the biological regulation of human growth and set the stage for further genetic analysis of this classical complex trait.

RESULTS

Identification of loci associated with height

We carried out a meta-analysis of GWA data for height that included 15,821 individuals from six studies: two type 2 diabetes case-control datasets (DGI⁴, $n = 2,978$; FUSION¹³, $n = 2,371$), two nested cancer case-control datasets (NHS¹⁴, $n = 2,286$; PLCO¹⁵, $n = 2,244$) and two datasets from population-based cohorts (KORA¹⁶, $n = 1,644$; SardiNIA¹⁷, $n = 4,305$) (Supplementary Table 1 online). All participants were of European ancestry. Because genome-wide genotyping in these studies was done on different platforms (Affymetrix 500K for DGI, KORA, and SARDINIA, Illumina 317K for FUSION and Illumina 500K for NHS and PLCO), we imputed genotypes for all polymorphic markers in the HapMap Phase II CEU reference panel in each GWA scan using the program MACH (Y. Li and G.R.A., unpublished data), thereby generating compatible datasets of 2,260,683 autosomal SNPs. Adult height was tested for association with these SNPs in each study under an additive genetic model, and association results were combined by meta-analysis using a weighted Z -score method (Methods). Whereas the distribution of test statistics for each individual GWA study was consistent with the expectation under the null hypothesis



(Fig. 1), the quantile-quantile plot of the meta-analysis results clearly showed a large excess of low P values at the right tail of the distribution, despite minimal evidence of overall systematic bias ($\lambda_{GC} = 1.089$; Fig. 2a). This result suggests that true associations with height variation, which were not discernable from the background in the individual studies, were brought to light in the combined analysis. Indeed, the second- and third-strongest association signals in these height meta-analysis results—*HMGA2* rs1042725 ($P = 2.6 \times 10^{-11}$) and *GDF5-UQCC* rs6060369 ($P = 1.9 \times 10^{-10}$)—have recently been shown to be robustly associated with stature in humans not selected for tall or short stature^{11,12}. These findings validate our meta-analytic approach and suggest that other loci associated with height are represented at or near the top of our results.

To distinguish true variants associated with height from other SNPs that could have achieved low P values by chance or confounding effects, and also to collect direct genotype data for associations based on imputed genotypes, we set up a two-stage follow-up strategy (Supplementary Fig. 1 online). In the first stage, we selected 78 SNPs representative of the top association signals (ranked by P values, and taking into account linkage disequilibrium (LD) to minimize redundancy); we then genotyped these 78 SNPs in a panel of European Americans ($n = 2,189$) ascertained from the near-ends of the normal height distribution (short, 5–10th percentile; tall, 90–95th percentile) (Supplementary Table 2 online). This panel has been used previously to replicate very strongly the *HMGA2* rs1042725 association¹². To decrease the number of false positives taken into the second stage and retain true associations with height, we selected for further study 29 SNPs that had an odds ratio in the European American panel that was consistent with the direction of the effect observed in the meta-analysis (Methods). We genotyped these SNPs in four large validation (replication) panels: all 29 SNPs were genotyped in the population-based FINRISK97 cohort ($n = 7,803$), and a subset was genotyped in the population-based KORA S4 ($n = 4,130$) and PPP ($n = 3,402$) cohorts and the type 2 diabetes case-control FUSION stage 2 panel

Figure 2 Quantile-quantile plots supporting the presence of additional loci associated with height. **(a)** Plot of 2,260,683 SNPs from the meta-analysis of the six GWA scans ($n = 15,821$). Each black triangle represents an observed statistic (defined as the $-\log_{10}(P)$) versus the corresponding expected statistic. The black squares correspond to the distribution of test statistics after removing markers correlated to the 12 height signals with $P < 5 \times 10^{-7}$ described in Table 1. The gray line corresponds to the null distribution. **(b)** Association results from Weedon *et al.*¹⁸ provide independent evidence that the top 10,000 SNPs from our meta-analysis exceed the null expectations (gray line). We selected the top 10,000 SNPs from our meta-analysis before (black triangles) and after (black squares) removing SNPs marking the known height loci (identified by us and in the accompanying manuscript) and retrieved the corresponding P values from Weedon *et al.* We show one-tailed P values because we corrected for the direction of effects, if needed. Inflation factors are unusually high because the analysis is restricted to the top 10,000 SNPs, which are likely enriched for SNPs that are truly associated with height variation.

($n = 2,466$) (Supplementary Tables 3–6 online). Because of logistic and technical issues, not all 29 SNPs could be genotyped in all four DNA panels, thus leading to a loss in power for some of these SNPs in our follow-up strategy. Nevertheless, these combined efforts led to the identification of 12 SNPs with combined $P < 5 \times 10^{-7}$ (using evidence from the meta-analysis and the validation panels except the European American tall-short (USHT) panel (*CHCHD7-RDHE2*, $P = 9 \times 10^{-6}$; Table 1). This indicates that loci with P values in this range are at least enriched for loci with valid associations with height. In addition, four loci showed overall suggestive evidence (combined $P < 5 \times 10^{-6}$) of association with adult height (Table 1). Although SNP rs2730245 at the *WDR60* locus has a combined $P = 3 \times 10^{-7}$, we chose to include this marker in our list of suggestive associations because, unlike the 12 loci in the top section of Table 1, this signal had a follow-up $P > 0.05$.

Characterization of signals associated with height

Population stratification is a possible strong confounder for association studies of height and other human phenotypes¹⁹. We took several steps to ensure that the association signals for height confirmed in our study were not due to population stratification. Association tests in the NHS and PLCO datasets were corrected for residual population structure using principal component methods²⁰; a similar analysis on the unrelated component of DGI did not change association results for the SNPs reported in Table 1 (Supplementary Table 8 online). An analysis of the FINRISK97 replication panels stratified for geographic origins within Finland did not alter the strength of the associations with height reported in Table 1 (Supplementary Table 9 online). Finally, using 279 variants known to correlate with the major axes of ancestry in European-derived populations²¹, we calculated a small inflation factor (λ) of 1.09 for our height meta-analysis results, suggesting that no substantial stratification is shown even by markers selected for this purpose. Taken together, these results indicate that the genetic associations with height found in our study are unlikely to be due to population stratification.

For the 16 SNPs identified with combined $P < 5 \times 10^{-6}$ (Table 1), there was, in the FINRISK97 panel, no evidence of departure from an additive genetic model ($P > 0.05$ for likelihood ratio test of additive

Table 1 Summary association results for 29 SNPs genotyped in the follow-up panels

Chromosome (position)	SNP	MAF (allele) ^a	Meta-analysis <i>P</i> beta (s.e.m.) ^b	Meta-analysis heterogeneity <i>I</i> ^{2c} (%)	Follow-up <i>P</i> beta (s.e.m.) ^b	Follow-up heterogeneity <i>I</i> ^{2c} (%)	Combined <i>P</i> beta (s.e.m.) ^d	USHT <i>P</i> OR (95% CI) ^e	Nearby genes ^f
Validated associations (combined <i>P</i> < 5 × 10⁻⁷)									
3 (142588268)	rs724016	0.48 (G)	5.0 × 10 ⁻¹² 0.461 (0.070)	0	2.5 × 10 ⁻¹¹ 0.307 (0.051)	71	8.3 × 10 ⁻²² 0.365 (0.038)	7.8 × 10 ⁻⁸ 1.4 (1.2–1.6)	ZBTB38
12 (64644614)	rs1042725	0.49 (T)	2.6 × 10 ⁻¹¹ -0.403 (0.070)	8	1.7 × 10 ⁻¹⁰ -0.493 (0.077)	0	2.7 × 10 ⁻²⁰ -0.484 (0.051)	4.2 × 10 ⁻⁶ 0.8 (0.7–0.9)	HMGA2
6 (1427445570)	rs4896582	0.27 (A)	3.2 × 10 ⁻⁸ -0.397 (0.077)	0	6.3 × 10 ⁻¹² -0.365 (0.058)	24	2.4 × 10 ⁻¹⁸ -0.378 (0.051)	2.2 × 10 ⁻⁵ 0.8 (0.7–0.9)	GPR126
6 (26341366)	rs10946808	0.28 (G)	3.3 × 10 ⁻⁸ -0.448 (0.083)	40	1.9 × 10 ⁻¹⁰ -0.314 (0.058)	63	3.8 × 10 ⁻¹⁷ -0.358 (0.045)	3.4 × 10 ⁻⁸ 0.7 (0.7–0.8)	HIST1H1D
20 (33370575)	rs6060369	0.36 (C)	1.9 × 10 ⁻¹⁰ 0.454 (0.077)	0	1.3 × 10 ⁻⁷ 0.410 (0.077)	0	1.4 × 10 ⁻¹⁶ 0.435 (0.051)	0.012 1.2 (1.0–1.3)	GDF5-UQCC
4 (146007626)	rs1492820	0.48 (G)	3.6 × 10 ⁻⁸ -0.435 (0.077)	0	3.9 × 10 ⁻⁵ -0.218 (0.051)	0	1.2 × 10 ⁻¹¹ -0.288 (0.038)	0.002 0.8 (0.7–0.9)	HHIP
14 (91529711)	rs8007661	0.30 (T)	8.9 × 10 ⁻⁸ -0.486 (0.090)	0	0.0015 -0.326 (0.102)	n.a.	5.5 × 10 ⁻¹⁰ -0.416 (0.064)	0.64 1.0 (0.9–1.1)	TRIP11-ATXN3
6 (105514355)	rs314277	0.13 (A)	5.9 × 10 ⁻⁹ 0.608 (0.109)	0	0.035 0.230 (0.102)	0	1.1 × 10 ⁻⁸ 0.410 (0.077)	0.26 1.1 (0.9–1.3)	LIN28B
19 (2121954)	rs12986413	0.45 (T)	2.0 × 10 ⁻⁵ 0.333 (0.077)	23	3.7 × 10 ⁻⁴ 0.275 (0.077)	60	2.9 × 10 ⁻⁸ 0.307 (0.051)	0.20 1.1 (1.0–1.2)	DOT1L
15 (82077496)	rs2562784	0.17 (G)	2.9 × 10 ⁻⁵ 0.307 (0.083)	3	5.5 × 10 ⁻⁴ 0.397 (0.115)	n.a.	6.4 × 10 ⁻⁸ 0.339 (0.064)	0.28 1.1 (1.0–1.2)	SH3GL3-ADAMTSL3
8 (57318152)	rs9650315	0.13 (T)	9.6 × 10 ⁻⁶ -0.474 (0.102)	46	0.010 -0.352 (0.134)	26	3.8 × 10 ⁻⁷ -0.429 (0.083)	9.0 × 10 ⁻⁶ 0.7 (0.6–0.8)	CHCHD7-RDHE2
7 (91901556)	rs2040494	0.50 (C)	4.8 × 10 ⁻⁵ -0.288 (0.077)	29	0.0020 -0.237 (0.077)	0	3.8 × 10 ⁻⁷ -0.262 (0.051)	0.18 0.9 (0.8–1.0)	CDK6
Suggestive associations (5 × 10⁻⁶ > combined <i>P</i> > 5 × 10⁻⁷)									
7 (158224265)	rs2730245	0.33 (G)	2.6 × 10 ⁻⁷ 0.410 (0.083)	4	0.082 0.179 (0.102)	23	3.0 × 10 ⁻⁷ 0.320 (0.064)	0.99 1.0 (0.9–1.1)	WDR60
9 (130493638)	rs7466269	0.33 (G)	1.2 × 10 ⁻⁵ -0.339 (0.077)	0	0.011 -0.198 (0.077)	0	7.5 × 10 ⁻⁷ -0.269 (0.058)	0.48 1.0 (0.9–1.1)	FUBP3
9 (116214350)	rs7869550	0.24 (G)	9.5 × 10 ⁻⁶ -0.429 (0.090)	0	0.18 -0.218 (0.090)	2	1.2 × 10 ⁻⁶ -0.326 (0.064)	0.58 1.0 (0.8–1.1)	PAPPA
17 (51785154)	rs12449568	0.47 (C)	4.7 × 10 ⁻⁶ 0.333 (0.077)	19	0.047 0.153 (0.077)	35	2.4 × 10 ⁻⁶ 0.250 (0.051)	0.49 1.0 (0.9–1.2)	ANKFN1
Others (combined <i>P</i> > 1 × 10⁻⁵)									
16 (615681)	rs763014	0.43 (C)	2.5 × 10 ⁻⁵ 0.307 (0.077)	41	0.033 0.166 (0.077)	59	5.1 × 10 ⁻⁶ 0.237 (0.058)	0.05 1.1 (1.0–1.3)	RAB40C
14 (36069800)	rs17104630	0.04 (G)	1.4 × 10 ⁻⁵ -0.621 (0.141)	0	0.062 -0.250 (0.128)	2	8.1 × 10 ⁻⁶ -0.422 (0.096)	0.02 0.8 (0.6–1.0)	NKX2-1
8 (41596148)	rs11786297	0.05 (G)	4.9 × 10 ⁻⁵ 0.544 (0.128)	20	0.10 0.320 (0.186)	52	3.9 × 10 ⁻⁵ 0.474 (0.102)	0.39 1.1 (0.9–1.4)	AGPAT6
14 (91477446)	rs3783937	0.28 (T)	5.5 × 10 ⁻⁵ -0.326 (0.083)	35	0.15 -0.128 (0.090)	0	8.2 × 10 ⁻⁵ -0.237 (0.064)	0.02 0.9 (0.8–1.0)	FBLN5
16 (2225358)	rs26840	0.43 (T)	1.6 × 10 ⁻⁴ 0.326 (0.077)	0	0.29 -0.128 (0.186)	46	1.5 × 10 ⁻⁴ 0.269 (0.064)	0.02 1.2 (1.0–1.3)	E4F1
5 (4573856)	rs1450822	0.48 (A)	4.1 × 10 ⁻⁴ 0.282 (0.077)	10	0.43 0.141 (0.186)	6	3.3 × 10 ⁻⁴ 0.262 (0.070)	0.21 1.1 (1.0–1.2)	
8 (129118629)	rs13249999	0.05 (T)	2.8 × 10 ⁻⁴ -0.768 (0.198)	18	0.30 -0.205 (0.198)	n.a.	3.6 × 10 ⁻⁴ -0.480 (0.141)	0.59 0.9 (0.8–1.2)	
20 (5034939)	rs6116651	0.10 (T)	4.8 × 10 ⁻⁵ -0.531 (0.122)	36	0.46 -0.122 (0.147)	0	4.7 × 10 ⁻⁴ -0.371 (0.096)	0.004 0.8 (0.6–0.9)	C20orf30
4 (4394990)	rs2916448	0.13 (C)	3.9 × 10 ⁻⁷ -0.531 (0.102)	0	0.67 0.070 (0.160)	23	5.5 × 10 ⁻⁴ -0.358 (0.090)	0.25 0.9 (0.8–1.1)	LYAR
4 (82511461)	rs1662845	0.35 (T)	5.7 × 10 ⁻⁵ 0.326 (0.083)	0	0.60 0.038 (0.077)	77	9.1 × 10 ⁻⁴ 0.179 (0.058)	8.5 × 10 ⁻⁶ 1.3 (1.2–1.5)	PRKG2
15 (77391837)	rs11858942	0.37 (G)	8.2 × 10 ⁻⁶ 0.339 (0.077)	0	0.86 -0.013 (0.083)	0	0.0015 0.173 (0.058)	0.54 1.0 (0.9–1.2)	TMED3
7 (50439131)	rs12540874	0.29 (G)	7.3 × 10 ⁻⁵ -0.288 (0.077)	0	0.91 0.006 (0.083)	0	0.0027 -0.160 (0.058)	0.98 1.0 (0.9–1.1)	GRB10
18 (48613000)	rs12958987	0.23 (T)	8.8 × 10 ⁻⁶ -0.339 (0.083)	0	0.16 0.154 (0.109)	n.a.	0.0045 -0.160 (0.064)	0.69 1.0 (0.9–1.1)	DCC

^aThe minor allele frequency (MAF) and corresponding allele are given for the HapMap European American CEU population, positive strand, Build NCBI 35. ^bEffect size (beta) and standard error (s.e.m.) are expressed in centimeters. The direction of the effect is given for the CEU minor allele. The meta-analytic *P* value is calculated using a weighted Z-score method. Effect sizes are calculated using the inverse variance method (fixed effect). ^cValues in bold have a Cochran's Q heterogeneity test *P* value < 0.05. ^dThe combined *P* value is calculated by combining the *P* values from the GWA meta-analysis and the follow-up panels using a weighted Z score method (results from the European American (USHT) tall-short panel are excluded from the combined analysis because of its specific ascertainment). The combined effect size is calculated using the inverse variance method (fixed effect), and by excluding results from the related component of DGI and the tall-short USHT panel. ^eThe odds ratio corresponds to the increased odds of being in the group of tall individuals for each additional minor allele. ^fNearby genes are defined as the closest genes to (200-kb window), and/or genes in LD with, the SNP. n.a., not applicable for SNPs genotyped in only one follow-up panel.




Figure 3 Analysis of combined effects. For each participant in the FINRISK97 panel with complete genotype at the 12 SNPs with $P < 5 \times 10^{-7}$ in **Table 1** ($n = 7,566$), we counted the number of height-increasing alleles to create a height score. Individuals with ≤ 8 or ≥ 16 'tall' alleles were grouped. For each height score group, in men and women separately, the mean \pm 95% confidence interval is plotted. The axis for men is on the left and the axis for women is on the right (same scale). The regression line in dark gray indicates that, for both men and women, each additional 'tall' allele increases height by 0.4 cm. The light gray histogram in the background represents the relative fraction of individuals in each height score group (height score ≤ 8 : 4.7%; height score 9: 6.2%; height score 10: 11.1%; height score 11: 15.5%; height score 12: 17.5%; height score 13: 15.6%; height score 14: 13.7%; height score 15: 8.6%; height score ≥ 16 : 7.1%).

versus unconstrained two degree-of-freedom test), no significant difference in effect size between males and females ($P > 0.05$), and no strong epistatic interactions between loci (the most significant interaction was observed between SNP rs1492820 and SNP rs10946808 ($P = 0.001$), which is not significant after correcting for the 120 pairwise tests of interaction done).

Explanatory power of loci associated with height

Each of the common height SNPs reported here explains a small fraction of the residual phenotypic variation in height (0.1–0.8%; **Supplementary Table 7**). When analyzed together, the additive effects of the 12 SNPs with combined $P < 5 \times 10^{-7}$ only contribute 2.0% of the height variation in the FINRISK97 panel, far from the estimated ~80–90% attributable to genetic variation. To assess the cumulative predictive value of this initial set of variants, we created a 'height score' by counting the number of height-increasing alleles (12 SNPs; height score 0–24) in each participant with complete genotype for these 12 SNPs in the FINRISK97 panel ($n = 7,566$). On average, males and females with ≤ 8 'tall' alleles (4.7% of FINRISK97) are 3.5 cm and 3.6 cm shorter than males and females with ≥ 16 'tall' alleles (7.1% of FINRISK97), respectively (**Fig. 3**). Individual effect sizes range from 0.3 cm per T allele for *CDK6* rs2040494 to 0.5 cm per C allele for *HMGA2* rs1042725 (**Table 1**).

DISCUSSION

Some of the SNPs reported here fall in or near strong candidate height genes, such as the recently described associations with *HMGA2* (ref. 12) and *GDF5-UQCC*¹¹, whereas others identify previously unsuspected loci. Together, these associations highlight biological pathways that are important in regulating human growth.

Hedgehog-interacting protein (*HHIP*; rs1492820) is a transcriptional target and an antagonist of Hedgehog signaling; it binds with high affinity to the three mammalian Hedgehog proteins²². The mouse homolog, *Hhip*, is expressed in the perichondrium, including regions flanking Indian hedgehog (*Ihh*) expression in the appendicular and axial skeleton. Ectopic overexpression of *Hhip* in mouse cartilage causes severe skeletal defects, including short-limbed dwarfism, a feature reminiscent of the phenotype observed in *Ihh* null mice^{22,23}.

We identified several associated SNPs in or near genes related to chromatin structure. In addition to *HMGA2*, which encodes a chromatin-binding protein, we found associations with a SNP (rs10946808) in a histone cluster on chromosome 6, a SNP (rs12986413) in the histone methyltransferase *DOT1L* gene and a SNP (rs724016) in an intron of the methyl-DNA-binding transcriptional repressor gene *ZBTB38*. It is currently unclear how genetic variation at these loci modulate height, but there is a precedent for a connection between regulation of chromatin structure and stature: Sotos syndrome (MIM117550), characterized by extreme tall stature, is caused by mutations and deletions in the histone methyltransferase gene *NSD1*. It would be interesting to test whether the height variants at *HMGA2*, the chromosome 6 histone cluster, *DOT1L* and *ZBTB38* modify clinical outcome in Sotos syndrome, or whether severe mutations in these genes, particularly *DOT1L*, could cause a Sotos syndrome-like phenotype.

That the variant rs1042725, strongly associated with adult and childhood height¹², falls in the 3' UTR of *HMGA2* is notable in part because *HMGA2* is the human gene with the greatest number of validated *let-7* microRNA binding sites^{24,25}. In fact, rs1042725 is 13 base pairs away from a *let-7* site, suggesting a possible mechanism of action whereby the SNP alters microRNA binding and therefore expression of *HMGA2*. When we examined our list of 12 height loci, we were somewhat surprised to find three additional previously described targets of *let-7*: the cell cycle regulator *CDK6* (ref. 26), the histone methyltransferase *DOT1L*²⁷ and the gene *LIN28B*²⁸. *PAPA*, a locus with a combined $P = 1.2 \times 10^{-6}$ in our study, also contains a predicted *let-7* binding site²⁷. Thus, genes that influence height seem to be enriched for validated or potential *let-7* targets: 5 of the 16 (31%) confirmed or suggestive loci associated with height have *let-7* binding sites, compared with 2% of the genes in the human genome (Fisher's exact test $P = 3 \times 10^{-5}$). Because microRNAs can co-regulate genes involved in the same biological process, it will be interesting to test whether the other targets of *let-7*, or *let-7* itself, are regulators of adult height.

There were also noteworthy candidate genes among the variants that showed strong but as yet less conclusive levels of significance for association with height in our meta-analysis of GWA studies and replication cohorts. A SNP 28 kb upstream of *PRKG2* (rs1662845), which encodes the cGMP-dependent protein kinase II (cGKII), showed strong association with height in our meta-analysis of GWA scans ($P = 5.7 \times 10^{-5}$), and in the same direction in the European American height panel ($P = 8.5 \times 10^{-6}$) and the FUSION stage 2 sample ($P = 0.001$), but not in the FINRISK97 ($P = 0.93$, opposite direction) and PPP ($P = 0.16$, opposite direction) panels. This locus is a very strong candidate for a role in height variation. First, *Prkg2*^{-/-} mice developed dwarfism that is caused by a severe defect in

endochondral ossification at the growth plates²⁹. Second, the naturally occurring Komeda miniature rat Ishikawa mutant, which has general longitudinal growth retardation, results from a deletion in the rat gene encoding cGKII³⁰. Therefore, in rodents, it is clear that cGKII has a role in skeletal growth, acting as a molecular switch between chondrocyte proliferation and differentiation. We predict that larger replication studies will demonstrate that common genetic variation at the *PRKG2* locus does contribute to height variation in humans, but it seems possible that there will also be heterogeneity among studies.

Several newly identified loci associated with height are located near genes with less immediately apparent connections to stature, including the G protein-coupled receptor gene *GPR126*, a locus that encompasses the thyroid hormone receptor interactor *TRIP11* and the ataxin *ATXN3* genes, a locus with the Huntingtin-interacting gene *SH3GL3* and the glycoprotein metalloprotease gene *ADAMTSL3* (the later often mutated in colon cancer³¹), a locus with gene *CHCHD7*, frequently fused to the *PLAG1* oncogene in salivary gland adenomas³², and the epidermal retinal dehydrogenase 2 gene *RDHE2*. Because of LD (Supplementary Fig. 2), it is possible that the causal alleles at these loci are not located in these genes; fine-mapping in larger cohorts or in populations of different ancestry may be required to pinpoint the relevant gene and functional variant(s). Alternatively, these genes may themselves influence height, and further work will be needed to elucidate the relevant pathways and mechanisms.

We note that the accompanying manuscript by Weedon *et al.*¹⁸ identifies association with height for several of the loci reported in our study (*ZBTB38*, *HMG2A*, *GDF5-UQCC*, *HHIP*, *SH3GL3-ADAMTSL3*, *CDK6*), and reports, as we do, a suggestive association for a SNP at the *FUBP3* locus ($P = 7.5 \times 10^{-7}$ in our study; $P = 2.0 \times 10^{-5}$ in Weedon *et al.*). *FUBP3*, a gene implicated in *c-myc* regulation, is therefore likely to represent an additional locus associated with height.

The variants associated with height that we validated do not have strong enough effects to generate detectable linkage signals³³. Three of our loci lie under previously reported height linkage peaks⁸: *ZBTB38*, lod score 2.03; *TRIP11-ATXN3*, lod score 2.01; and *CDK6*, lod score 2.26. However, because 17.6% of the genome overlaps with a height linkage peak with lod score > 2 , the number of such co-localizations is not greater than expected by chance (3 observed versus 2.12 expected). It remains possible that some genes harbor both common and rare variants that influence height, so some overlaps may yet emerge between associated and linked loci that have a real genetic basis. Furthermore, regions of linkage may indicate the locations of rare variants or other types of genetic variation that are not well captured by our current association methods.

As expected, the estimated effect sizes in the GWA meta-analysis were generally larger than the effect sizes observed in replication samples, because of the well-known ‘winner’s curse’ phenomenon³⁴. Perhaps less well appreciated is that the magnitude of the winner’s curse effect depends on the underlying distribution of effect sizes: the greater the number of variants with small effects, the more likely it is that one or more of these variants will approach genome-wide significance even in a study that is not well powered to detect these very modest effects³⁵. Such variants will then prove difficult to convincingly replicate, unless very large replication cohorts are used. Thus, it is possible that even some of the initial associations that we failed to replicate will eventually be validated.

Given the modest effect sizes observed for the validated variants associated with height (Table 1; average = 0.4 cm per additional allele), it is not surprising that the quantile-quantile plots for the individual GWA studies are essentially indistinguishable from the null

expectation (Fig. 1). Indeed, we calculate that a study of 3,000 unrelated individuals has 1% power to detect a variant (minor allele frequency 10%) that increases height by 0.4 cm at a statistical threshold of $P = 1 \times 10^{-5}$. In comparison, a study of 16,000 individuals has 72% power to identify the same variant (in fact, there is a slight loss in power when using meta-analytic methods to combine results). Our discovery of valid associations by combining individual studies with nearly null *P*-value distributions highlights the importance of using large datasets to find common variants with small effects. When we remove the 12 validated height variants (and nearby correlated SNPs) from the meta-analysis results, the number of low *P* values still exceeds the null expectation (Fig. 2a, filled squares). Furthermore, the 10,000 SNPs with the best *P* values also showed excess evidence of association in an independent meta-analysis¹⁸, even when all loci known to be associated with height were excluded (Fig. 2b). These results indicate that there are other associations with common alleles yet to be discovered, but that our meta-analysis is not sufficiently powered to identify these associations because the effect sizes are small.

Our results have several implications. First, they outline a role for multiple genes and biological pathways that were previously not known to regulate height, substantiating the ability of unbiased genetic approaches to yield new biological insights. The identification of these genes not only expands our knowledge of human growth but also promotes these genes as candidates for as yet unexplained syndromes of severe tall or short stature. Second, these findings convincingly confirm the polygenic nature of height, a classic complex trait, and demonstrate that, at least for this trait, increasingly large GWA studies can uncover increasing numbers of associated loci. Third, each variant makes only a small contribution to phenotypic variation (although determining the total contribution of each of the loci reported here requires much more comprehensive resequencing and genotyping); thus, either many hundreds of common variants influence complex traits such as height and/or other genetic contributors (for example, gene–gene or gene–environment interactions, rare variants with large effects, or uncaptured genomic features such as structural polymorphisms) will play a significant role. In particular, because the quality-control criteria used in the GWA studies analyzed here would have removed SNPs affected by copy number polymorphisms, we cannot conclude anything regarding the role of these variants on adult height. With the development of new platforms and improved analytical tools applicable to large cohorts, it is likely that the role of common structural variants on human complex traits such as adult height will soon be elucidated. Finally, if height is indeed a good model for other complex traits, these results suggest that large meta-analyses of GWA studies will provide insights not only into human growth but also into the underlying biological mechanisms of common disease.

METHODS

Description of genome-wide association study samples. The individuals analyzed by the Diabetes Genetics Initiative (DGI) have been described elsewhere⁴. In total, there were 1,464 type 2 diabetes cases and 1,467 matched controls of European ancestry from Finland and Sweden. The Finland–United States investigation of non-insulin-dependent diabetes mellitus genetics (FUSION) GWA study included 1,161 Finnish type 2 diabetes (T2D) cases, 1,174 normal glucose tolerant (NGT) controls, and 122 offspring of case-control pairs¹³. Cases and controls were matched as previously described, taking into account age, sex and birth province within Finland. The KORA genome-wide association study samples were recruited from the KORA S3 survey, which is a population-based sample from the general population living in the region of Augsburg, Southern Germany. The 1,644 study participants had a German passport and were of European origin¹⁶. The Nurses’ Health

Study (NHS) GWA scan included DNA from 2,286 registered nurses of European ancestry: 1,145 postmenopausal women with invasive breast cancer and 1,142 matched controls¹⁴. The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) GWA scan included 1,172 non-Hispanic prostate cancer cases of European ancestry and 1,105 matched controls¹⁵. The SardinIA GWAS examined a total of 4,305 related individuals participating in a longitudinal study of aging-related quantitative traits in the Ogliastra region of Sardinia, Italy¹⁷. More details can be found in the **Supplementary Methods** online.

Description of follow-up samples. The European American ($n = 2,189$) sample is a tall-short study with subjects ranking in the 5–10th percentiles in adult height (short women, 152–155 cm; short men, 164–168 cm) and in the 90–95th percentiles in adult height (tall women, 170–175 cm; tall men, 185–191 cm)¹⁹. All individuals were self-described ‘white’ or ‘of European descent’. All subjects were born in the United States, and all of their grandparents were born in either the United States or Europe. Using the Genetic Power Calculator³⁶ and assuming a purely additive genetic effect across the whole phenotypic distribution, we calculated that the study design of the European American tall-short panel provides 33.0, 79.0 and 98.6% power to detect variants that explain ≥ 0.1 , 0.25 and 0.5% of the phenotypic variation in height, respectively (at an α -threshold of 0.01), and power was greater to meet our less stringent screening criteria of any odds ratio in the same direction than the effect observed in the meta-analysis. FINRISK 1997 is one of the population-based risk factor surveys carried out by the National Public Health Institute of Finland every five years³⁷, and was approved by the Ethical Committee of the National Public Health Institute (decision number 38/96). The sample was drawn from the National Population Register for five geographical areas. The FUSION stage 2 study includes a series of cases and controls matched to take into account age, sex, and birth province within Finland¹³. The KORA S4 samples were recruited from Augsburg, Southern Germany, and do not overlap with the KORA S3 population. Prevalence, Prediction and Prevention of Diabetes (PPP) in the Botnia study is a population-based study started in 2004 to study the epidemiology of type 2 diabetes. More details can be found in the **Supplementary Methods**. These studies were approved by the appropriate ethical review boards.

Genotype imputation. Because the GWA scans used different genotyping platforms, we imputed genotypes for all polymorphic HapMap SNPs in each scan, using a hidden Markov model as implemented in MACH (Y. Li and G.R.A., unpublished data). This approach allowed us to evaluate association at the same SNPs in all scans. The imputation method combines genotype data from each sample with the HapMap CEU samples (July 2006 phased haplotype release) and then infers the unobserved genotypes probabilistically. The inference relies on the identification of stretches of haplotype shared between study samples and individuals in HapMap CEU reference panel. For each SNP in each individual, imputation results are summarized as an ‘allele dosage’ defined as the expected number of copies of the minor allele at that SNP (a fractional value between 0.0 and 2.0). As previously described, r^2 between each imputed genotype and the true underlying genotype is estimated and serves as a quality-control metric (rsq_hat in **Supplementary Table 7**). We chose an estimated $r^2 > 0.3$ as a threshold to flag and discard low-quality imputed SNPs (ref. 13 and Y. Li and G.R.A., unpublished data).

Association analyses. For all studies, except for the European American height panel, we converted height to Z score, taking into account sex, age and disease status when appropriate. For the DGI, KORA S3, NHS, PLCO, FINRISK97, KORA S4 and PPP cohorts, we carried out association testing using a regression framework implemented in PLINK³⁸ for genotyped markers, and in MACH2QTL (Y. Li and G.R.A., unpublished data), which takes into account dosage information (0.0–2.0), for imputed SNPs. For DGI, we used a genomic control method to correct for the presence of related individuals. Association testing in the FUSION and SardinIA datasets was done for both genotyped and imputed SNPs using a method that allows for relatedness, estimating regression coefficients in the context of a variance components model³⁹. Statistical analysis for the European American tall-short panel was done using a Cochran-Mantel-Haenszel (CMH) test³⁸ stratified by the European region of origin of the grandparents.

Meta-analysis. Association results presented in this manuscript take into account the posterior probability on each imputed genotype. To combine results, we used a weighted Z -score method:

$$z_w = z_i \times \sqrt{N_i/N_{\text{tot}}}$$

z_w is the weighted Z score from which the meta-analytic two-tailed P value is calculated, z_i is the Z score from study i (calculated as the cumulative normal probability density for the corresponding one-tailed P value, adjusted if needed by subtracting the P value from one when the direction of the effect is reversed), N_i is the sample size of study i and N_{tot} is the total sample size. In total, we combined association results at 2,260,683 autosomal SNPs in 15,821 individuals (DGI, $n = 2,978$; FUSION, $n = 2,371$; KORA, $n = 1,644$; NHS, $n = 2,286$; PLCO, $n = 2,244$; SardinIA, $n = 4,305$). The I^2 statistic⁴⁰ and Cochran’s Q test were used to assess heterogeneity.

Genotyping and quality control. Genotyping of the initial GWA studies is described elsewhere^{4,11,13–15}, except for KORA, which is described in the **Supplementary Methods**. Genotyping in the European American height panel and the replication panels FINRISK97, PPP, FUSION stage 2 and KORA S4 was done using the Sequenom MassARRAY iPLEX platform. From the meta-analysis, we selected 78 SNPs (three iPLEX pools; six SNPs failed) for genotyping in the European American tall-short panel ($n = 2,189$): SNPs were first ranked using their meta-analytic P values, and then binned using the LD pattern from the HapMap Phase II CEU population (SNPs with $r^2 > 0.5$ to a SNP with a lower P value were binned together with that SNP). When a locus had more than one high-ranking bin, we only genotyped the most significant SNP such that only one SNP per locus or gene was genotyped. Because of the specific design of this DNA panel (near-ends of the height distribution) but also because effect sizes on height are small (and were inflated by the winner’s curse in the meta-analysis), we promoted for genotyping in larger follow-up cohorts markers that had an odds ratio consistent with the direction of the effect observed in the meta-analysis (without considering the magnitude of the European American CMH P values). For the FINRISK97 panel, 29 SNPs were attempted and two failed. For the PPP panel, 23 SNPs were attempted and two failed. For the FUSION stage 2 panel, 27 SNPs were attempted and one failed. For the KORA S4 panel, five SNPs were attempted and one failed. For all passing SNPs, the genotyping success rate was $> 96\%$ and the consensus error rate, estimated from replicates, was $< 0.1\%$.

Accession numbers. Genbank Entrez Gene: data for validated loci associated with height are available with accession codes 253461 (ZBTB38), 8091 (HMG2), 57211 (GPR126) 3007 (HIST1H1D), 8200 (GDF5), 55245 (UQCC), 64399 (HHIP), 9321 (TRIP11), 4287 (ATXN3), 389421 (LIN28B), 84444 (DOT1L), 6457 (SH3GL3), 57188 (ADAMTSL3), 79145 (CHCHD7), 195814 (RDHE2), 1021 (CDK6).

URLs. DGI GWA study, <http://www.broad.mit.edu/diabetes/>; Markov Chain Haplotyping Package, <http://www.sph.umich.edu/csg/abecasis/MaCH>.

Note: Supplementary information is available on the Nature Genetics website.

ACKNOWLEDGMENTS

We thank members of our laboratories for helpful discussion, and gratefully acknowledge all of the participants in the studies. Contributing members for the DGI, FUSION, KORA and SardinIA GWA scans are listed in the **Supplementary Note**. The authors acknowledge C. Chen of Bioinformed Consulting Services Inc. for expert programming, and L. Qi for his assistance. The authors thank C. Berg and P. Prorok, Division of Cancer Prevention, National Cancer Institute, the Screening Center investigators and staff of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, T. Riley and staff, Information Management Services, Inc., and B. O’Brien and staff, Westat, Inc. KORA gratefully acknowledges the contribution of T. Meitinger and all other members of the GSF genotyping staff in generating the SNP dataset. We thank the Mayor and the administration in Lanusei for providing and furnishing the clinic site; and the mayors of Ilbono, Arzana and Elini, the head of the local Public Health Unit ASL4. Support for this work was provided by the following: US National Institutes of Health grants 5P01CA087969 and CA49449 (S.E. Hankinson), 5U01CA098233 (D.J.H.), DK62370 (M.B.), DK72193 (K.L.M.), HG02651 and HL084729 (G.R.A.); Novartis Institutes for BioMedical Research (D. Altshuler);

March of Dimes grant 6-FY04-61 (J.N.H.); EU Projects GenomEUtwin grant QL2-CT-2002-01254 and the Center of Excellence in Complex Disease Genetics of the Academy of Finland (L.P.); the Sigrid Juselius Foundation (L.C.G., V.S. and PPP); the Finnish Diabetes Research Foundation and the Folkhälsan Research Foundation and Clinical Research Institute HUCH (L.C.G.); this research was supported (in part) by the intramural Research Program of the NIH, National Institute on Aging; the PLCO research was supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics and by contracts from the Division of Cancer Prevention, National Cancer Institute, NIH, DHHS; KORA/MONICA Augsburg studies were financed by the GSF-National Research Center for Environment and Health, Munich/Neuherberg, Germany and supported by grants from the German Federal Ministry of Education and Research (BMBF); part of this work by KORA was supported by the German National Genome Research Network (NGFN), the Munich Center of Health Sciences (MC Health) as part of LMUinnovativ, and a subcontract of the 5 R01 DK 075787 by the NIH/NIDDK to the GSF-National Research Center for Environment and Health (to J.N.H.).

AUTHOR CONTRIBUTIONS

G.L., A.U.J., C. Gieger, F.R.S., S.I.B., S.S., S.E. and B.F.V. performed analyses. G.L. performed the meta-analysis and selected markers for follow-up. J.L.B., C. Guiducci, T.I. and R.H. genotyped markers in some of the follow-up panels. G.L. and J.N.H. wrote the manuscript, with inputs from the other authors, especially M.B. and S.I.B. V.L., L.C.G., B.I. and J.N.H. are investigators of the DGI and Botnia studies. L.P. and V.S. are investigators of the FINRISK97 study. M.U., D.S. and G.R.A. are investigators of the SardiNIA study. K.B.J., S.J.C. and R.B.H. are investigators of the PLCO study. I.M.H. and H.-E.W. are investigators of the KORA study. M.B. and K.L.M. are investigators of the FUSION study. F.B.H., P.K. and D.J.H. are investigators of the NHS. D.J.H., R.B.H., G.R.A., H.-E.W., K.L.M. and J.N.H. led this study. All authors read and approved the final manuscript.

Published online at <http://www.nature.com/naturegenetics>

Reprints and permissions information is available online at <http://npg.nature.com/reprintsandpermissions>

- Hirschhorn, J.N. & Daly, M.J. Genome-wide association studies for common diseases and complex traits. *Nat. Rev. Genet.* **6**, 95–108 (2005).
- The International HapMap Consortium. A haplotype map of the human genome. *Nature* **437**, 1299–1320 (2005).
- Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* **447**, 661–678 (2007).
- Saxena, R. *et al.* Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. *Science* **316**, 1331–1336 (2007).
- Frayling, T.M. *et al.* A common variant in the *FTO* gene is associated with body mass index and predisposes to childhood and adult obesity. *Science* **316**, 889–894 (2007).
- Scuteri, A. *et al.* Genome-wide association scan shows genetic variants in the *FTO* gene are associated with obesity-related traits. *PLoS Genet.* **3**, e115 (2007).
- Fisher, R.A. The correlation between relatives on the supposition of Mendelian inheritance. *Transactions of the Royal Society of Edinburgh* **52**, 399–433 (1918).
- Perola, M. *et al.* Combined genome scans for body stature in 6,602 European twins: evidence for common Caucasian loci. *PLoS Genet.* **3**, e97 (2007).
- Mathias, R.A. *et al.* Comparison of year-of-exam- and age-matched estimates of heritability in the Framingham Heart Study data. *BMC Genet.* **4** (Suppl 1), S36 (2003).
- Gunnell, D. *et al.* Height, leg length, and cancer risk: a systematic review. *Epidemiol. Rev.* **23**, 313–342 (2001).
- Sanna, S. *et al.* Common variants in the *GDF5-UQCC* region are associated with variation in human height. *Nat. Genet.* **40**, 198–203 (2008).
- Weedon, M.N. *et al.* A common variant of *HMGA2* is associated with adult and childhood height in the general population. *Nat. Genet.* **39**, 1245–1250 (2007).
- Scott, L.J. *et al.* A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. *Science* **316**, 1341–1345 (2007).
- Hunter, D.J. *et al.* A genome-wide association study identifies alleles in *FGFR2* associated with risk of sporadic postmenopausal breast cancer. *Nat. Genet.* **39**, 870–874 (2007).
- Yeager, M. *et al.* Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. *Nat. Genet.* **39**, 645–649 (2007).
- Wichmann, H.E., Gieger, C. & Illig, T. KORA-gen—resource for population genetics, controls and a broad spectrum of disease phenotypes. *Gesundheitswesen* **67** (Suppl. 1), S26–S30 (2005).
- Pilia, G. *et al.* Heritability of cardiovascular and personality traits in 6,148 Sardinians. *PLoS Genet.* **2**, e132 (2006).
- Weedon, M.N. *et al.* Genome-wide association analysis identifies 20 loci that influence adult height. *Nat. Genet.* advance online publication, doi: 10.1038/ng.121 (6 April 2008).
- Campbell, C.D. *et al.* Demonstrating stratification in a European-American population. *Nat. Genet.* **37**, 868–872 (2005).
- Price, A.L. *et al.* Principal components corrects for stratification in genome-wide association studies. *Nat. Genet.* **38**, 904–909 (2006).
- Price, A.L. *et al.* Discerning the ancestry of European Americans in genetic association studies. *PLoS Genet.* **4**, e236 (2008).
- Chuang, P.T. & McMahon, A.P. Vertebrate Hedgehog signalling modulated by induction of a Hedgehog-binding protein. *Nature* **397**, 617–621 (1999).
- St-Jacques, B., Hammerschmidt, M. & McMahon, A.P. Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. *Genes Dev.* **13**, 2072–2086 (1999).
- Mayr, C., Hemann, M.T. & Bartel, D.P. Disrupting the pairing between *let-7* and *Hmga2* enhances oncogenic transformation. *Science* **315**, 1576–1579 (2007).
- Lee, Y.S. & Dutta, A. The tumor suppressor microRNA *let-7* represses the *HMGA2* oncogene. *Genes Dev.* **21**, 1025–1030 (2007).
- Johnson, C.D. *et al.* The *let-7* microRNA represses cell proliferation pathways in human cells. *Cancer Res.* **67**, 7713–7722 (2007).
- Krek, A. *et al.* Combinatorial microRNA target predictions. *Nat. Genet.* **37**, 495–500 (2005).
- Guo, Y. *et al.* Identification and characterization of *lin-28* homolog B (*LIN28B*) in human hepatocellular carcinoma. *Gene* **384**, 51–61 (2006).
- Pfeifer, A. *et al.* Intestinal secretory defects and dwarfism in mice lacking cGMP-dependent protein kinase II. *Science* **274**, 2082–2086 (1996).
- Chikuda, H. *et al.* Cyclic GMP-dependent protein kinase II is a molecular switch from proliferation to hypertrophic differentiation of chondrocytes. *Genes Dev.* **18**, 2418–2429 (2004).
- Sjoberg, T. *et al.* The consensus coding sequences of human breast and colorectal cancers. *Science* **314**, 268–274 (2006).
- Asp, J., Persson, F., Kost-Alimova, M. & Stenman, G. *CHCHD7-PLAG1* and *TCEA1-PLAG1* gene fusions resulting from cryptic, intrachromosomal 8q rearrangements in pleomorphic salivary gland adenomas. *Genes Chromosomes Cancer* **45**, 820–828 (2006).
- Hirschhorn, J.N. *et al.* Genomewide linkage analysis of stature in multiple populations reveals several regions with evidence of linkage to adult height. *Am. J. Hum. Genet.* **69**, 106–116 (2001).
- Lohmueller, K.E., Pearce, C.L., Pike, M., Lander, E.S. & Hirschhorn, J.N. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. *Nat. Genet.* **33**, 177–182 (2003).
- Zöllner, S. & Pritchard, J.K. Overcoming the winner's curse: estimating penetrance parameters from case-control data. *Am. J. Hum. Genet.* **80**, 605–615 (2007).
- Purcell, S., Cherny, S.S. & Sham, P.C. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. *Bioinformatics* **19**, 149–150 (2003).
- Vartiainen, E. *et al.* Cardiovascular risk factor changes in Finland, 1972–1997. *Int. J. Epidemiol.* **29**, 49–56 (2000).
- Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.* **81**, 559–575 (2007).
- Chen, W.M. & Abecasis, G.R. Family-based association tests for genomewide association scans. *Am. J. Hum. Genet.* **81**, 913–926 (2007).
- Higgins, J.P., Thompson, S.G., Deeks, J.J. & Altman, D.G. Measuring inconsistency in meta-analyses. *Br. Med. J.* **327**, 557–560 (2003).